Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1

✍ Scribed by Vijayshankar Ganesh Sivanandam; Sam Laurel Stephen; Ruben Hernandez-Alcoceba; Pilar Alzuguren; Maider Zabala; Nico van Rooijen; Cheng Qian; Irina Berger; Marie-Luise Gross; Jesus Prieto; Stefan Kochanek

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 283 KB
• Volume: 10
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.1244

✦ Synopsis

Abstract

Background

Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor growth.

Methods

To sequester VEGF, we tested, in a subcutaneous LLC tumor model, ‘gutless’ high‐capacity adenovirus vectors expressing the soluble VEGF receptor 1 (sflt1) in a liver‐specific manner, either in a constitutive or in a RU486 induced manner.

Results

High serum levels of sflt1 were observed upon in vivo injection of both vectors. Despite the differences in expression kinetics, both modes of sflt1 expression resulted in significant though transient suppression of tumor growth. Unexpectedly, constitutive but not intermittent sflt1 expression resulted in ascites and death of all animals. Morphological analyses by light and electron microscopy indicated that the animals had died from a nephropathy, which apparently was due to the blockade of VEGF function.

Conclusions

Although confirming earlier results of toxic effects of prolonged VEGF sequestration, the present study suggests that therapeutic anti‐tumor effects can be achieved without side‐effects with intermittent VEGF blockade or the use of drugs with short half‐lives, as shown by the use of an inducible gene expression system. Copyright © 2008 John Wiley & Sons, Ltd.